An interventional study of Structured exercise program and Ergonomic training in Occupational Diseases and Musculoskeletal Pain, sponsored by Uskudar University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 25 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Uskudar University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This randomized controlled trial will investigate whether a 12-week structured exercise program added to ergonomic training reduces pain and pain-related disability and improves quality of life more than ergonomic training alone in oil industry workers with chronic musculoskeletal pain. Forty workers aged 25-50 years with musculoskeletal pain lasting at least 3 months will be randomly assigned to either ergonomic training plus exercise or ergonomic training only. Both groups will receive two 45-minute ergonomic training sessions specific to oil-field work (weeks 1 and 6) and a printed brochure. The exercise group will additionally perform a phased neuromuscular and resistance exercise program 3 days per week for 12 weeks, partly supervised at the worksite and partly home/worksite-based. Pain intensity (visual analogue scale), pain-related disability (Pain Disability Index), quality of life (SF-12), regional musculoskeletal symptoms (Extended Nordic Musculoskeletal Questionnaire) and sleep quality (Pittsburgh Sleep Quality Index) will be assessed by an assessor blinded to group allocation at baseline and after 12 weeks.
Background: Work-related musculoskeletal disorders are a leading cause of lost productivity and disability. Oil and gas installations combine heavy lifting, repetitive work, awkward postures, vibrating tools, prolonged standing and shift work; musculoskeletal symptom prevalence of 71-89% has been reported in this workforce. Multicomponent workplace programs combining exercise, ergonomics and education provide the most consistent benefit for pain and function, and ergonomic-educational interventions alone have reduced symptoms in oil and gas workers; however, no randomized controlled trial has evaluated the added value of exercise in this population.
Design: Prospective, assessor-blinded, two-arm, parallel-group, 1:1 randomized controlled trial conducted at a single oil industry facility. The study will be reported according to CONSORT and TIDieR. Participants will be randomized using a computer-generated list with variable block sizes (4 and 6); allocation will be concealed in sequentially numbered, opaque, sealed envelopes prepared by an investigator not involved in treatment or assessment.
Interventions: Both groups receive ergonomic training specific to oil-field work: two 45-minute face-to-face group sessions (8-12 workers) at weeks 1 and 6 covering musculoskeletal risk factors, NIOSH lifting principles, valve/flange and overhead work, hand-arm and whole-body vibration, prolonged standing and grated floors, control-room/office ergonomics, shift work and sleep hygiene, and a 5-minute micro-break routine, plus a printed brochure and micro-break card, with weekly reminder messages for 12 weeks. The exercise group additionally performs a 12-week structured program, 3 non-consecutive days per week, 45 minutes per session (36 sessions): weeks 1-2 fully supervised at the facility in groups of 4-6, weeks 3-12 one supervised and two home/worksite-based sessions per week supported by an illustrated brochure and guided video. Each session comprises warm-up and mobility (6 min), neuromuscular stabilization (12 min), resistance strengthening with elastic bands and light loads (14 min), job-specific functional exercise such as box lifting and carrying (6 min) and stretching (7 min). The program progresses through three phases (motor control and activation, weeks 1-4; endurance and strength, weeks 5-8; job-specific functional loading, weeks 9-12) with intensity targeted at Borg CR-10 4-6 and load progression by the 2-for-2 rule. The control group receives weekly ergonomic reminder messages and a telephone call every 2 weeks to equalize contact; the exercise program is offered to the control group after final assessment.
Outcomes: Assessments at baseline (T0) and at the end of the 12-week intervention (T1) by a physiotherapist blinded to group allocation. Primary outcome: pain intensity on a 0-10 cm visual analogue scale. Secondary outcomes: Pain Disability Index (0-70), SF-12 physical and mental component summaries, regional symptom prevalence on the Extended Nordic Musculoskeletal Questionnaire, and sleep quality on the Pittsburgh Sleep Quality Index (exploratory). Process measures: session adherence, Borg CR-10 and adverse events.
Sample size: A priori power analysis (G*Power 3.1; repeated-measures ANOVA, within-between interaction; f = 0.25, alpha = 0.05, power = 0.80, 2 groups, 2 measurements, correlation 0.50) indicated 34 participants; allowing for 15-20% attrition, 40 participants (20 per group) will be enrolled.
Analysis: Intention-to-treat with multiple imputation; per-protocol (adherence ≥70%) as sensitivity analysis. Primary outcome analyzed with 2 × 2 mixed-design repeated-measures ANOVA (group × time interaction) or ANCOVA on the week-12 score adjusted for baseline. Secondary continuous outcomes analyzed in the same way; Benjamini-Hochberg correction for secondary outcomes. Dichotomous Nordic data analyzed with McNemar and chi-square/Fisher tests. Effect sizes (partial eta squared, Cohen d) with 95% CIs, proportion exceeding the minimal clinically important difference and number needed to treat will be reported. Significance p \< 0.05.
49 studies on the registry are indexed under Occupational Diseases; 11 are open to participants now.
This study's planned enrollment of 40 is below the median of 126 across 24 interventional studies indexed under Occupational Diseases.
Browse Occupational Diseases studies →Uskudar University is the lead sponsor of 173 studies on the registry; 38 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oil-field-specific ergonomic training (two 45-min sessions at weeks 1 and 6, brochure, weekly reminders) plus a 12-week phased neuromuscular and resistance exercise program, 3 days/week, 45 min/session, partly supervised at the worksite.
Behavioral: Structured exercise program
The same oil-field-specific ergonomic training (two 45-min sessions at weeks 1 and 6, brochure, weekly reminders) and a telephone call every 2 weeks for contact equalization; no exercise program during the study. The exercise program is offered after final assessment.
Behavioral: Structured exercise program · Behavioral: Ergonomic training
12 weeks, 3 non-consecutive days/week, 45 min/session (36 sessions). Weeks 1-2 fully supervised by a physiotherapist at the facility (groups of 4-6); weeks 3-12 one supervised + two home/worksite-based sessions per week with illustrated brochure and guided video. Three phases: motor control/activation (weeks 1-4, body weight and light bands), endurance/strength (weeks 5-8, medium bands, 5-8 kg), job-specific functional loading (weeks 9-12, heavy bands, 8-12 kg). Intensity Borg CR-10 4-6; progression by 2-for-2 rule; pain rule ≤3/10 during exercise returning to baseline within 24 h.
Two 45-minute face-to-face group sessions (8-12 workers) at weeks 1 and 6 delivered by a physiotherapist (short presentation, practical demonstration and teach-back, discussion). Content: oil-field musculoskeletal risk factors; NIOSH lifting principles; valve/flange and overhead work; vibrating tools and hand-arm vibration; prolonged standing, grated floors and stairs; vehicle/cabin and whole-body vibration; control-room/office ergonomics; shift schedules and sleep hygiene; 5-minute micro-break routine. Printed brochure and micro-break card; weekly reminder messages for 12 weeks.
Change in pain intensity (Visual Analogue Scale)
Average pain over the past week marked on a 10 cm horizontal line (0 = no pain, 10 = worst imaginable pain), measured in cm. Lower scores indicate less pain. Minimal clinically important difference ≥2 cm or ≥30%.
Time frame: Baseline, Week 12
Change in pain-related disability (Pain Disability Index)
7 items (family/home responsibilities, recreation, social activity, occupation, sexual behavior, self-care, life-support activity) each rated 0-10; total 0-70, higher scores indicate greater disability. Turkish version validated.
Time frame: Baseline, Week 12
Change in health-related quality of life (SF-12)
Physical Component Summary (PCS) and Mental Component Summary (MCS) scores, each 0-100; higher scores indicate better quality of life. Turkish version validated.
Time frame: Baseline, Week 12
Change in regional musculoskeletal symptom prevalence (Extended Nordic Musculoskeletal Questionnaire)
Presence of symptoms (yes/no) in the last 7 days and last 12 months and activity limitation in nine body regions (neck, shoulders, upper back, lower back, elbows, wrists/hands, hips/thighs, knees, ankles/feet). Turkish version validated.
Time frame: Baseline, Week 12
Change in sleep quality (Pittsburgh Sleep Quality Index) - exploratory
Seven component scores (0-3) summed to a global score 0-21; scores \>5 indicate poor sleep quality. Turkish version validated.
Time frame: Baseline, Week 12
Plan to share: Undecided — De-identified individual participant data may be made available from the principal investigator upon reasonable request after publication of the main results.
Start is estimated for Dec 2026; primary completion for May 2027, 5 months later.
Of 14 interventional studies with no phase under Occupational Diseases, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 12. This study's planned 5 months is close to that.
Occupational Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.